Therapix Biosciences Provides Update on Planned Merger With Destiny Biosciences Global Corp.


TEL AVIV, Israel, Oct. 10, 2019 /PRNewswire/ — Therapix Biosciences Ltd. (“Therapix” or the “Company”) (NASDAQ: TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced today an update on its planned merger with…


Author: HEDGE

Executive Editor and Founder of Hedge Was Founded in January 22, 2008. Learn more about HEDGEaccordingly